Cysteamine / AIF Cancer Research Results

Cyste, Cysteamine: Click to Expand ⟱
Features:
Cysteamine is a prescription drug, approved for treating cystinosis
-it is not sold over-the-counter as a dietary supplement.
-In contrast, related compounds like N-acetylcysteine (NAC) and pantethine are widely available supplements and can indirectly support cysteamine-related pathways (e.g., antioxidant defenses and CoA metabolism).

-Pantethine: Precursor to CoA, which breaks down into cysteamine
-Pantothenic Acid (Vitamin B5): Required for CoA synthesis

-Cysteamine increases glutathione (GSH) levels, reducing oxidative stress, a major contributor to AD pathology.
-Some studies suggest that cysteamine increases brain-derived neurotrophic factor (BDNF) levels
-Cysteamine has been observed to reduce amyloid plaque burden in animal models of AD.

Cysteamine — Cysteamine is a low-molecular-weight aminothiol and cystine-depleting prescription drug approved for nephropathic cystinosis, where it acts through lysosomal thiol-disulfide exchange to reduce cystine accumulation. It is formally classified as an oral small-molecule cystine-depleting agent and endogenous CoA-catabolism-derived aminothiol. Standard abbreviations include cysteamine, cysteamine bitartrate, mercaptamine, and Cyste. It is not an over-the-counter dietary supplement; related pathway-supporting compounds include pantethine, pantothenic acid, and N-acetylcysteine, but these are not equivalent to cysteamine.

Primary mechanisms (ranked):

  1. Lysosomal cystine depletion through thiol-disulfide exchange, producing cysteine and cysteine-cysteamine mixed disulfide that can exit lysosomes.
  2. MMP2, MMP9, and MMP14 suppression in glioblastoma models, reducing invasion and migration at micromolar concentrations.
  3. TGM2 modulation, with downstream effects on EMT markers, invasion, and TRAIL sensitivity in selected cancer models.
  4. Redox remodeling through cysteine and glutathione modulation, generally cytoprotective in normal cells but context-dependent in cancer cells.
  5. NRF2/ARE activation, mainly documented as neuroprotective and normal-cell stress-response biology rather than established anti-cancer selectivity.
  6. Mitochondrial stress and apoptosis signaling at higher or context-specific concentrations, including AIF/caspase-linked effects in sensitive models.

Bioavailability / PK relevance: Cysteamine bitartrate is orally bioavailable, with immediate-release and delayed-release prescription formulations. Delayed-release products are designed for prolonged exposure; reported clinical peak plasma levels are typically in the low micromolar to tens-of-micromolar range, depending on formulation, food timing, and patient context.

In-vitro vs systemic exposure relevance: The most translational oncology signal is the GBM anti-invasion/MMP effect reported around micromolar to low sub-millimolar exposure; higher millimolar cytotoxic findings are less likely to be directly achievable systemically and should be treated as high-concentration in-vitro effects.

Clinical evidence status: Approved clinical use is for nephropathic cystinosis, not cancer. Oncology evidence is preclinical, mainly in-vitro and mechanistic, with adjunct potential for invasion, migration, redox, and sensitization biology but no established cancer-treatment indication.

Cysteamine Cancer Mechanism Matrix

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 MMP2 MMP9 MMP14 invasion axis MMP activity ↓; invasion ↓; migration ↓ Likely wound-remodeling effects possible (context-dependent) G Anti-invasive and anti-migratory Most cancer-relevant direct cysteamine finding; strongest current support is glioblastoma cell-line data, not clinical oncology data.
2 TGM2 EMT resistance axis TGM2 ↓; N-cadherin ↓; E-cadherin ↑; TRAIL sensitivity ↑ with cystamine in selected models TGM2-linked repair and matrix biology may be altered (context-dependent) G Reduced EMT-like behavior and possible sensitization Cysteamine and cystamine biology overlap but should not be treated as identical; cystamine is commonly used as the TGM2 inhibitor in older cancer studies.
3 Lysosomal cystine depletion Cystine handling ↔ or ↓ (model-dependent) Lysosomal cystine ↓ in cystinosis cells R Cystine-depleting pharmacologic identity Core approved mechanism; cancer relevance is indirect unless tumor dependence on lysosomal cystine handling is demonstrated.
4 Cysteine glutathione redox axis GSH ↑ or ↓ (context-dependent); ROS buffering ↑ or oxidative stress ↑ (model-dependent) Cysteine ↑; GSH ↑; oxidative stress ↓ R G Redox remodeling Potentially double-edged in oncology: cytoprotection may protect normal tissue but may also reinforce tumor antioxidant capacity in some settings.
5 NRF2 ARE stress response NRF2 ↑ (context-dependent); tumor-protective risk possible NRF2 ↑; ARE genes ↑; neuroprotection ↑ R G Stress-response activation Mechanistically relevant but not a clean anti-cancer axis; NRF2 activation may be protective in normal cells and potentially undesirable in NRF2-dependent tumors.
6 Mitochondrial apoptosis stress AIF translocation ↑; apoptosis ↑ (high concentration only) Epithelial toxicity possible (high concentration only) R G Cytotoxic stress at higher exposure Less translational for systemic oncology unless exposure and selectivity are demonstrated.
7 Radiosensitization or radioprotection Radiation response ↔ (insufficient direct oncology evidence) Radioprotection ↑ historically described for aminothiols R G Potential normal-cell protection Could be beneficial or counterproductive depending on timing relative to radiotherapy; not established as a cancer adjunct.
8 Clinical Translation Constraint Anti-invasive micromolar effects may be plausible; cytotoxic millimolar effects are less plausible systemically Prescription safety constraints; GI intolerance; odor; rash; electrolyte issues; rare serious toxicities G Deployment limitation Regulatory status supports cystinosis use only. Cancer use remains investigational and would require tumor-specific exposure, safety, and combination data.

TSF legend:

P: 0–30 min

R: 30 min–3 hr

G: >3 hr



AD relevance: Cysteamine and cystamine have moderate mechanistic relevance to neurodegeneration through cysteine/GSH support, NRF2/ARE activation, BDNF modulation, heat-shock response, and mitochondrial stress buffering. For Alzheimer’s disease specifically, the evidence is not clinical proof of disease modification; it is best classified as preclinical or mechanistic neuroprotection extrapolated from neurodegenerative models, with limited direct AD-specific translational support.

Primary AD mechanisms (ranked):

  1. Redox support through cysteine and glutathione elevation, potentially reducing oxidative stress.
  2. NRF2/ARE activation, potentially supporting neuronal and glial antioxidant defenses.
  3. BDNF elevation and secretory-pathway modulation, mainly supported in Huntington disease models but relevant to neurotrophic resilience.
  4. Mitochondrial and protein-stress modulation, including heat-shock and transglutaminase-linked effects.
  5. Amyloid-related effects remain indirect or weakly supported relative to core AD therapeutic mechanisms.

Clinical evidence status: AD evidence is preclinical/mechanistic. Cysteamine is not an established AD therapy and should not be entered as clinically validated for AD disease modification.

Cysteamine AD Mechanism Matrix

Rank Pathway / Axis Modulation TSF Primary Effect Notes / Interpretation
1 Cysteine glutathione redox support Cysteine ↑; GSH ↑; oxidative stress ↓ R G Neuroprotective redox buffering Mechanistically plausible for AD oxidative stress but not AD-clinically proven.
2 NRF2 ARE antioxidant response NRF2 ↑; ARE transcription ↑ R G Stress-response activation Supported in neurotoxin models; AD relevance is pathway-level rather than direct therapeutic validation.
3 BDNF neurotrophic axis BDNF ↑ G Neuronal resilience support Best supported in Huntington disease models; relevant to AD biology but indirect.
4 TGM2 and protein stress TGM2 ↓ or activity ↓ (context-dependent); heat-shock proteins ↑ G Protein-homeostasis modulation Potentially relevant to neurodegenerative protein aggregation biology.
5 Amyloid pathology Aβ burden ↔ or ↓ (weak direct support) G Uncertain anti-amyloid relevance Do not classify as a primary AD anti-amyloid intervention without stronger source support.
6 Clinical Translation Constraint Prescription-only; AD clinical validation lacking G Evidence limitation Mechanistic neuroprotection is stronger than disease-specific AD clinical evidence.

TSF legend:

P: 0–30 min

R: 30 min–3 hr

G: >3 hr
AIF, Apoptosis-Inducing Factor: Click to Expand ⟱
Source:
Type:
AIF is a mitochondrial oxidoreductase that contributes to cell death programmes and participates in the assembly of the respiratory chain.
Nuclear translocation of AIF occurs during cell death and has been associated with human disorders. Expression Levels:
AIF is often found to be overexpressed in several types of cancers, including breast, lung, and colorectal cancers.
The expression of AIF can vary significantly between different tumor types and even among patients with the same type of cancer.
Survival Rates:
High levels of AIF expression have been associated with poor prognosis in certain cancers, indicating a potential role in tumor aggressiveness and metastasis.
Conversely, low AIF expression may correlate with better survival outcomes in some contexts.
Overexpression: In many cancers, AIF is overexpressed, which is often associated with poor prognosis, increased tumor aggressiveness, and resistance to therapy.
Scientific Papers found: Click to Expand⟱
6257- Cyste,    Cystamine induces AIF-mediated apoptosis through glutathione depletion
- vitro+vivo, Var, NA
AIF↑, GSH↓, neuroP↑,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

GSH↓, 1,  

Mitochondria & Bioenergetics ⓘ

AIF↑, 1,  

Functional Outcomes ⓘ

neuroP↑, 1,  
Total Targets: 3

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: AIF, Apoptosis-Inducing Factor
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:369  Target#:520  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page